March 4, 2013

CAS databases provide millions of journal article references from more than 10,000 major scientific journals worldwide, patent and patent family references from 63 patent authorities around the world, and other reputable web sources.  

The following patent record is from the CAplusSM database.


Patent Number: WO 2012174342        
Title: Spiro[cyclohexane-oxazolidinone] derivatives as TRPV4 antagonists and their preparation            
Inventor(s): Brooks, Carl; Cheung, Mui; Eidam, Hilary Schenck; Goodman, Krista B.; Hammond, Marlys; Hilfiker, Mark A.; Patterson, Jaclyn R.; Stoy, Patrick; Ye, Guosen
Patent Assignee(s): GlaxoSmithKline LLC, USA
Source: PCT Int. Appl., 91pp. CODEN: PIXXD2
Language: English


The invention relates to spirocarbamate analogs of formula I, pharmaceutical compns. containing them and their use as TRPV4 antagonists. Compds. of formula I wherein n is 1, 2 and 3; X is CR4 and N; R1 is H, C1-3 alkyl, CH2OH, CH2OMe, CH2OBn, etc.; each R2 is independently H, CN, CF3, halo, etc.; R3 is H, C1-2 alkyl, CF3 and OH; R4 is H, halo, and C1-3 alkyl; A is (CH2)0-2-Ph, (CH2)0-2-naphthyl, (CH2)0-2-CO-Ph, etc.; and pharmaceutically acceptable salts thereof, are claimed.  Example compound II was prepared by amination and ring opening of 1-[(3S,5S)-1-oxaspiro[2.5]oct-5-ylmethyl]-1H-benzimidazole-6-carbonitrile with 3-bromobenzylamine; the resulting 1-[[(1S,SS)-3-((((3-bromophenyl)methyl)amino)methyl)-3-hydroxycyclohexyl]methyl]-1H-benzimidazole-6-carbonitrile, which underwent cyclization with CDI to give compound II.  All the invention compds. were evaluated for their TRPV4 antagonistic activity.  It was determined that the invention compds. exhibited IC50 values in the range of 0.001 nM to 1.

View the full-text patent here.

Note: Titles and abstracts for patent records in CAplus are routinely enhanced to better describe the claimed invention. In this example, CAS enhanced both the abstract and title using additional information found in the patent. The original title of the PCT patent publication is TRPV4 antagonists. For the CAplus record, this title was enhanced to read Spiro[cyclohexane-oxazolidinone] derivatives as TRPV4 antagonists and their preparation.

Recent News

    March 17, 2015 | New Content Provides Regulatory
    Professionals with Additional Value
    February 9, 2015 | Major New STN Release Delivers
    Essential Biomedical and Patent Content to IP
    January 26, 2015
 | Annual MEDLINE Reload on STN
    Features Enhanced Clinical Trial Information and the
    2015 MeSH Thesaurus
                                                                     More News >> 

 Media Contact

 Name: Rhonda Ross
 Phone: 614-447-3624